Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $177.00 million as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2025-03-10
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $177.00M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $163.10M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $150.60M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $155.60M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2024-12-31 | $177.00M 10-K · filed 2025-03-10 | |
| 2023-12-31 | $163.10M 10-K · filed 2025-03-10 | |
| 2022-12-31 | $150.60M 10-K · filed 2024-03-07 | |
| 2021-12-31 | $155.60M 10-K · filed 2022-03-10 | |
| 2020-12-31 | $169.90M 10-K · filed 2021-03-11 | |
| 2019-12-31 | $164.00M 10-K · filed 2020-03-12 | |
| 2018-12-31 | $93.80M 10-K · filed 2019-03-14 | |
| 2017-12-31 | $162.60M 10-K · filed 2018-03-15 | |
| 2016-12-31 | $171.10M 10-K · filed 2017-03-16 | |
| 2015-12-31 | $168.80M 10-K · filed 2016-03-15 | |
| 2014-12-31 | $122.45M 10-K · filed 2015-03-11 | |
| 2014-09-30 | $3.58M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $2.44M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.15M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $2.80M 10-Q · filed 2014-11-07 | $99.10M 10-K · filed 2014-03-17 |
| 2012-12-31 | $78.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |